CO5200850A1 - PHARMACEUTICAL COMPOSITION FOR PROFILAXIS AND TREATMENT OF SYMPTOMS ASSOCIATED WITH THE FLU, INFLUENZA AND SIMILAR DISEASES AND PROCEDURE FOR APPLICATION - Google Patents

PHARMACEUTICAL COMPOSITION FOR PROFILAXIS AND TREATMENT OF SYMPTOMS ASSOCIATED WITH THE FLU, INFLUENZA AND SIMILAR DISEASES AND PROCEDURE FOR APPLICATION

Info

Publication number
CO5200850A1
CO5200850A1 CO00057176A CO00057176A CO5200850A1 CO 5200850 A1 CO5200850 A1 CO 5200850A1 CO 00057176 A CO00057176 A CO 00057176A CO 00057176 A CO00057176 A CO 00057176A CO 5200850 A1 CO5200850 A1 CO 5200850A1
Authority
CO
Colombia
Prior art keywords
influenza
treatment
profilaxis
flu
procedure
Prior art date
Application number
CO00057176A
Other languages
Spanish (es)
Inventor
Seymour Gantenberg Nicholas
Jr Robert Ernest Singer
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of CO5200850A1 publication Critical patent/CO5200850A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención se refiere a una composición que incluye una fitoalexina estilbénica usada en un método para la profilaxis y tratamiento de síntomas del resfriado y similares a la influenza que comprende la administración de dicha composición a un sujeto, la cual tiene la estructura: <EMI FILE="00057176_1" ID="1" IMF=JPEG > en donde R1, R2, R3, R4, R5 y R6 independientemente se seleccionan de hidrógeno e hidroxi; y sales o ésteres medicinalmente aceptables de éstos.The present invention relates to a composition that includes a stylogenic phytoalexin used in a method for the prophylaxis and treatment of cold and influenza-like symptoms comprising the administration of said composition to a subject, which has the structure: <EMI FILE = "00057176_1" ID = "1" MFI = JPEG> where R1, R2, R3, R4, R5 and R6 are independently selected from hydrogen and hydroxy; and medicinally acceptable salts or esters thereof.

CO00057176A 1999-07-30 2000-07-31 PHARMACEUTICAL COMPOSITION FOR PROFILAXIS AND TREATMENT OF SYMPTOMS ASSOCIATED WITH THE FLU, INFLUENZA AND SIMILAR DISEASES AND PROCEDURE FOR APPLICATION CO5200850A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36494499A 1999-07-30 1999-07-30

Publications (1)

Publication Number Publication Date
CO5200850A1 true CO5200850A1 (en) 2002-09-27

Family

ID=23436803

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00057176A CO5200850A1 (en) 1999-07-30 2000-07-31 PHARMACEUTICAL COMPOSITION FOR PROFILAXIS AND TREATMENT OF SYMPTOMS ASSOCIATED WITH THE FLU, INFLUENZA AND SIMILAR DISEASES AND PROCEDURE FOR APPLICATION

Country Status (10)

Country Link
EP (1) EP1221949A2 (en)
JP (1) JP2003505500A (en)
CN (1) CN1377262A (en)
AU (1) AU6240200A (en)
CA (1) CA2379703A1 (en)
CO (1) CO5200850A1 (en)
HK (1) HK1049104A1 (en)
PE (1) PE20010540A1 (en)
TR (1) TR200200246T2 (en)
WO (1) WO2001008671A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878751B1 (en) 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders
ITRM20020562A1 (en) * 2002-11-06 2004-05-07 Sigma Tau Ind Farmaceuti USE OF THE RESVERATROL FOR THE PREPARATION OF A USEFUL DRUG FOR THE TREATMENT OF INFLUENCE VIRUS INFECTIONS.
RU2007132963A (en) * 2005-02-04 2009-03-10 Петер ХЕГЕР (DE) METHOD FOR PRODUCING HYDROXYSTILBEN CONTAINING EXTRACT OF MEDICINAL RAW MATERIAL
EP1844784B1 (en) * 2006-03-28 2010-04-21 Epitech Group S.r.l. A pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system
CN100453071C (en) * 2006-11-03 2009-01-21 李万忠 Oral resveratrol multi-phase liposome and preparation method thereof
WO2008136173A1 (en) * 2007-04-20 2008-11-13 Ochanomizu University Adipocyte differentiation inhibitor containing stilbene derivative as active ingredient
ES2703737T3 (en) 2008-01-08 2019-03-12 David Rubin Method and compositions to preserve wine
FR2933871B1 (en) * 2008-07-18 2012-12-14 Yvery FORMULATION FOR IMPROVING THE BIOAVAILABILITY OF A HYDROPHOBIC MOLECULE
DK2544705T3 (en) * 2010-03-12 2016-09-19 Synairgen Res Ltd INTERFERON BETA TO USE IN THE LOWER AIR TRANSMISSION CAUSED BY INFLUENZA
JP5848042B2 (en) 2011-06-29 2016-01-27 株式会社ロッテ Eye fatigue inhibiting composition and food and drink containing the same
US20140303260A1 (en) * 2011-10-19 2014-10-09 Nad Life Pty Ltd Pharmaceutical compositions of resveratrol
CN106581028A (en) * 2016-11-30 2017-04-26 南宁市浩特竹鼠养殖场 Western medicine for curing cold of bamboo rat and preparation method of western medicine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0753359A (en) * 1993-06-11 1995-02-28 Kao Corp Lipoxygenase inhibitor
FR2778337B1 (en) * 1998-05-05 2001-08-31 Inst Nat Sante Rech Med ARYLHYDROCARBON RECEPTOR LIGAND ANTAGONISTS
AU4084599A (en) * 1998-05-18 1999-12-06 Oklahoma Medical Research Foundation Resveratrol inhibition of myeloperoxidase
US6197834B1 (en) * 1998-09-01 2001-03-06 Northeastern Ohio Universities College Of Medicine Method of inhibiting formation of infectious herpes virus particles
ATE324105T1 (en) * 1998-09-08 2006-05-15 Cornell Res Foundation Inc USE OF CYCLOOXYGENASE-2 INHIBITORS TO TREAT INFLAMMATORY DISEASES OF THE HEAD AND NECK

Also Published As

Publication number Publication date
JP2003505500A (en) 2003-02-12
HK1049104A1 (en) 2003-05-02
CN1377262A (en) 2002-10-30
WO2001008671A2 (en) 2001-02-08
CA2379703A1 (en) 2001-02-08
EP1221949A2 (en) 2002-07-17
TR200200246T2 (en) 2002-09-23
WO2001008671A3 (en) 2002-05-02
AU6240200A (en) 2001-02-19
PE20010540A1 (en) 2001-05-15

Similar Documents

Publication Publication Date Title
ES2524458T3 (en) DNase for the treatment of male subfertility
AR026610A1 (en) A PIRROLIDINACETAMIDE DERIVATIVE ONLY OR IN COMBINATION FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
DE60143393D1 (en) MODIFIED FORMS PHARMACEUTICALLY ACTIVE AGENTS AND USES THEREOF
CO5160320A1 (en) METHODS AND COMPOSITIONS FOR THE PREVENTION OF TOLERANCE TO MEDICINES DAS.
CL2008003938A1 (en) Use of escitalopram or a pharmaceutically acceptable salt thereof to prepare a medicament useful in the treatment of post-traumatic stress disorder (divisional sol. 1799-00).
JP2005532372A5 (en)
UY28041A1 (en) LOW DOSE METHODS FOR THE TREATMENT OF DISORDERS IN WHICH TNFA&#39;S ACTIVITY IS HARMFUL.
ATE376832T1 (en) DELAYED RELEASE FORMULATIONS OF OXYMORPHONE
CO5200850A1 (en) PHARMACEUTICAL COMPOSITION FOR PROFILAXIS AND TREATMENT OF SYMPTOMS ASSOCIATED WITH THE FLU, INFLUENZA AND SIMILAR DISEASES AND PROCEDURE FOR APPLICATION
BR0114799A (en) Cyanophenoxy carboxylic acid compounds and compositions for releasing active agents
AR034900A1 (en) USE OF AN EFFECTIVE AMOUNT OF A PDE4 INHIBITOR AND AN ANTI-POLINERGIC AGENT, WELL IN COMBINED FORM ONLY OR SEPARATELY, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, METHOD TO PREPARE THEM, AND USE OF A COMPOSITION THAT INCLUDES AN EFFECTIVE AMOUNT OF A PDD AN EFFECTIVE AMOUNT
BR9509019A (en) Process for manufacturing pharmaceutical dosage units and tablet free of organic solvents
DK1296972T3 (en) Arylmethylamine derivatives for use as tryptase inhibitors
DE60322075D1 (en) PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS
ES2170143T3 (en) COMPOSITIONS THAT INCLUDE HALOFANTRINE IN A SPECIAL FORM.
DK1082131T3 (en) Immunoregulator
AR032614A1 (en) CONTROLLED ORAL ADMINISTRATION SYSTEM FOR DAILY INTAKE OF CIPROFLOXACINE
AR039162A1 (en) VENLAFAXINA FORMULATIONS OF EXTENDED LIBERATION
CO5690571A2 (en) SYNERGIC COMBINATION INCLUDING ROFLUMILAS AND (R, R) -FORMOTEROL
AR018376A1 (en) PHARMACEUTICAL COMPOSITIONS THAT CAN BE DISPERSED IN A SPONTANEOUS WAY AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
NO20031650D0 (en) New medicines for liver diseases
BG105984A (en) Osanetant in the treatment of mood disorders
DK1227826T3 (en) Compositions comprising an extract of Perna canaliculus, methylsulfonylmethane and glucosamide and the use thereof
BRPI0412506A (en) autologous cells that induce self-tolerance of monocytically originated and their use in pharmaceutical preparations
DE50005714D1 (en) PHARMACEUTICAL COMPOSITION, COMPREHENSIVE EUCALYPTUS AND ORANGE OIL

Legal Events

Date Code Title Description
FA Application withdrawn